![Eric van der Putten](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Eric van der Putten
Directeur/Membre du Conseil chez
Mimetas BV
Profil
Eric van der Putten is currently a Non-Executive Director at Mimetas BV and a Partner at Aglaia Management BV since 2014.
He was previously the Chief Executive Officer & Director at Modra Pharmaceuticals BV from 2016 to 2018.
Postes actifs de Eric van der Putten
| Sociétés | Poste | Début |
|---|---|---|
Aglaia Management BV
 Aglaia Management BV Investment ManagersFinance Aglaia's investment strategy focuses on seed and early-stage biomedical ventures exclusively in oncology. They invest primarily in preclinical and early-clinical development opportunities from research institutes based in The Netherlands. They also consider transactions with biomedical partners in Europe and in North America. They seek to invest in new tools and techniques in addition to components of contemporary drug development, such as production and selection systems for biomedical products, vehicles for drug delivery and drug targeting, diagnostic tools and essays, micro-array applications, screening assays, drug targets, drugs and drug systems. Aglaia is an active investment partner in driving product development. In addition to providing capital, they draw on their biomedical industry network and knowledge. They identify trends and formulate operating strategies. They seek to bring on board new investors and may also participate themselves in subsequent rounds of financing. | Private Equity Investor | 01/09/2014 |
Mimetas BV
 Mimetas BV BiotechnologyHealth Technology Develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models | Directeur/Membre du Conseil | - |
Anciens postes connus de Eric van der Putten
| Sociétés | Poste | Fin |
|---|---|---|
Modra Pharmaceuticals BV
 Modra Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Designs and develops oral formulations of commonly used anti-cancer drugs | Directeur Général | 19/12/2018 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
7
Relations au 1er degré
3
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Aglaia Management BV
Aglaia Management BV Investment ManagersFinance Aglaia's investment strategy focuses on seed and early-stage biomedical ventures exclusively in oncology. They invest primarily in preclinical and early-clinical development opportunities from research institutes based in The Netherlands. They also consider transactions with biomedical partners in Europe and in North America. They seek to invest in new tools and techniques in addition to components of contemporary drug development, such as production and selection systems for biomedical products, vehicles for drug delivery and drug targeting, diagnostic tools and essays, micro-array applications, screening assays, drug targets, drugs and drug systems. Aglaia is an active investment partner in driving product development. In addition to providing capital, they draw on their biomedical industry network and knowledge. They identify trends and formulate operating strategies. They seek to bring on board new investors and may also participate themselves in subsequent rounds of financing. | Finance |
Mimetas BV
Mimetas BV BiotechnologyHealth Technology Develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models | Health Technology |
Modra Pharmaceuticals BV
Modra Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Designs and develops oral formulations of commonly used anti-cancer drugs | Health Technology |
